Serina Therapeutics posts investor deck outlining POZ platform, lead Parkinson’s candidate SER-252 Phase 1b study

• Serina outlined a milestone-driven CNS strategy centered on lead program SER-252, a POZ-apomorphine product candidate for advanced Parkinson’s disease.
• SER-252 Phase 1b registrational study underway; first patient dosed February 2026; SAD Cohort 1 (n=8) dosing completed July 2026.
• Blinded safety, tolerability, PK review for SAD Cohort 1 scheduled for August 2026; SAD topline data targeted for 1Q 2027.
• Regulatory plan targets a 505(b)(2) NDA; SER-252 designed for controlled release with an on-body enFuse device aiming for twice-weekly dosing.
• Balance sheet update cited USD 21.2 million private placement gross proceeds; USD 24.5 million cash at March 31, 2026; USD 5.2 million additional gross proceeds received in April.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Serina Therapeutics Inc. published the original content used to generate this news brief on July 28, 2026, and is solely responsible for the information contained therein.